Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up

Antiviral Therapy

Volumn 5, Issue 1, 2000, Pages 65-70

  Clevenbergh, P ^a   Durant, J ^a   Halfon, P ^b   Del Giudice, P ^a   Mondain, V ^a   Montagne, N ^c   Schapiro, J M ^d   Boucher, C A B ^e   Dellamonica, P ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b Virology Department   (France)

^c Bonnet Hospital   (France)

^d National Haemophilia Centre   (Israel)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT PLANNING; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE;

EID: 0034065841     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
2. Perrin L & Telenti A. HIV Treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280:1871-1873.
3. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F43.
4. Palmer S, Shafer RW & Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999; 13:661-667.
5. Patick AK, Zhang M, Hertogs K, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Antiviral Therapy 1998; 3 (Suppl. 1):39.